Meriofert

Human luteinising hormone and human follicle‑stimulating hormone, the active ingredients in Meriofert, are gonadotropins presented as a solution for injection for intramuscular or subcutaneous use. They are employed to stimulate ovarian follicular development and induce ovulation in women with infertility related to anovulation.\n\nGNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin preparation that acts on the hypothalamic‑pituitary‑ovarian axis to support reproductive function.\n\nInfertility due to anovulation: supports follicular growth and induces ovulation in women who do not ovulate spontaneously.\nControlled ovarian stimulation: enhances follicle development for timed egg retrieval in assisted reproduction cycles.\nAssisted reproductive technology: provides the hormonal support required for in‑vitro fertilisation and related procedures.

Meriofert may cause a range of adverse reactions following injection.\n\nCommon Side Effects:\n- Injection site pain or erythema\n- Mild abdominal discomfort\n- Nausea or vomiting\n- Headache\n- Transient ovarian cyst formation\n\nSerious or Rare Side Effects:\n- Ovarian hyperstimulation syndrome (OHSS)\n- Multiple pregnancy\n- Severe allergic reaction (anaphylaxis)\n- Thromboembolic events\n- Significant ovarian torsion

When using Meriofert, clinicians should observe several safety measures.\n\nMonitor ovarian response: perform serial ultrasound and estradiol assessments.\nAvoid in active ovarian cysts: postpone treatment until resolution.\nUse with caution in thyroid disease: adjust therapy as needed.\nConsider risk of OHSS: limit dose escalation in high‑responders.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other medications that affect ovarian stimulation or hormonal balance.\n\nMajor Interactions (Avoid):\n- GnRH agonists: may amplify ovarian response, increasing OHSS risk.\n- Estrogen‑containing contraceptives: can blunt therapeutic effect.\n- Concurrent gonadotropins: additive stimulation may lead to excessive follicular development.\n\nModerate Interactions (Monitor Closely):\n- Thyroid hormone therapy: may require dose adjustment.\n- Corticosteroids: can influence hormone metabolism.\n- Anticoagulants: monitor for bleeding at injection sites.